CORRESP 1 filename1.htm

BioLineRx Ltd.
Modi’in Technology Park
2 HaMa’ayan Street
Modi’in 7177871, Israel

January 11, 2021
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.  20549
BioLineRx Ltd.
Registration Statement on Form F-3
File No. 333-251857


Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioLineRx Ltd. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-3 (File No. 333-251857) of the Registrant (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will be declared effective at 4:00 p.m., Eastern Time, on January 11, 2021 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

Very truly yours,

       By: /s/ Philip A. Serlin
       Name: Philip A. Serlin
       Title: Chief Executive Officer

cc: Gary Emmanuel (McDermott Will & Emery LLP)